Evidence map›Paper›PMID 38593220›Full record

ArticleAnnals of the New York Academy of Sciences2024

Long COVID and post-acute sequelae of SARS-CoV-2 pathogenesis and treatment: A Keystone Symposia report.

Matthew S Durstenfeld, Shannon Weiman, Michael Holtzman, Catherine Blish, Resia Pretorius, Steven G Deeks

Abstract read
In one paragraph

Article in Annals of the New York Academy of Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew S DurstenfeldDepartment of Medicine, University of California, San Francisco, California, USA.
Shannon WeimanKeystone Symposia, Silverthorne, Colorado, USA.
Michael HoltzmanDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Catherine BlishStanford Immunology Program and Department of Medicine, Stanford University, Stanford, California, USA.
Resia PretoriusDepartment of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, California, USA.

Funding

Defining and Controlling Airway DiseaseR35HL145242 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2019 to 2025
$6.6M
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)K12HL143961 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y., HUANG, LAURENCE · 2018 to 2022
$1.8M
NHLBI NIH HHS K12 HL143961NHLBI NIH HHS R35 HL145242
6 · The paper itself

Abstract

In 2023, the Keystone Symposia held the first international scientific conference convening research leaders investigating the pathology of post-acute sequelae of COVID-19 (PASC) or Long COVID, a growing and urgent public health priority. In this report, we present insights from the talks and workshops presented during this meeting and highlight key themes regarding what researchers have discovered regarding the underlying biology of PASC and directions toward future treatment. Several themes have emerged in the biology, with inflammation and other immune alterations being the most common focus, potentially related to viral persistence, latent virus reactivation, and/or tissue damage and dysfunction, especially of the endothelium, nervous system, and mitochondria. In order to develop safe and effective treatments for people with PASC, critical next steps should focus on the replication of major findings regarding potential mechanisms, disentangling pathogenic mechanisms from downstream effects, development of cellular and animal models, mechanism-focused randomized, placebo-controlled trials, and closer collaboration between people with lived experience, scientists, and other stakeholders. Ultimately, by learning from other post-infectious syndromes, the knowledge gained may help not only those with PASC/Long COVID, but also those with other post-infectious syndromes.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeSARS-CoV-2COVID-19 Drug TreatmentHumansconference reportLong COVIDpathogenesispost‐acute sequelae of COVID‐19post‐viral conditionstreatment

Identifiers

PMID38593220
PMCPMC11500513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.